Wuhan YZY Biopharma Co Ltd (02496.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 31Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.5x

Market Cap

HKD 639.70M

MomentumView details →

1D Return

−8.33%

YTD Return

−58.85%

RSI (14)

1.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.5x

Market Cap

HKD 639.70M

RSI (14)

1.2

MomentumView details →

1D Return

−8.33%

YTD Return

−58.85%

ProfitabilityView details →

Gross Margin

16.27%

Net Margin

−114.69%

EBITDA Margin

−105.28%

ROE (TTM)

183.31%

ROA (TTM)

−55.54%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

−21.36%

EPS YoY

+4.28%

FCF YoY

+59.70%

Revenue CAGR 3Y

+206.46%

EPS CAGR 3Y

+16.00%

EBITDA YoY

+3.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−2.41x

Current Ratio

0.66x

Quick Ratio

0.64x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

84.79M

Net Income (TTM)

−97.25M

Op. CF (TTM)

−39.98M

Latest newsMore news →

Youshiyou Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of 33.143 million RMB, down 10.9% year-on-year, and a narrowed net loss of 6.26 million RMB compared to a loss of 58.834 million RMB in the same period last year.7d ago

Similar companies

Cutia Therapeutics02487.HK Bright Minds Biosciences Inc.DRUG OmniAb, Inc.OABI MapLight Therapeutics, Inc.MPLT Valneva SEVALN Contineum Therapeutics, Inc. Class A Common StockCTNM Find similar companies →

Latest newsMore news →

Youshiyou Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of 33.143 million RMB, down 10.9% year-on-year, and a narrowed net loss of 6.26 million RMB compared to a loss of 58.834 million RMB in the same period last year.7d ago